CDR101 / CDR-Life - LARVOL DELTA

Preclinical Assessment of CDR101 – a BCMAxCD3xPD-L1 Trispecific Antibody with Superior Anti-Tumor Efficacy (ASH 2021) - "In contrast to high-affinity PD-L1 immune checkpoint inhibitors, CDR101 selectively inhibits PD-L1 at the immune synapse preventing on-target off-tumor effects. This is expected to translate into a decreased incidence of immune related adverse events (irAEs) and better efficacy arguing for a high clinical potential and swift translation into the clinic."

IO biomarker • Preclinical • Hematological Malignancies • Immune Modulation • Inflammation • Multiple Myeloma • Oncology • IL2RA • SDC1

CDR-Life Announces Positive Preclinical Data on CDR101 Program Presented at the American Society of Hematology’s 2021 Annual Meeting (GlobeNewswire) - "CDR-Life Inc...announced that one of the Company’s pharmacology experts, Dr. Melissa Vrohlings, presented preclinical data on CDR101, a next generation BCMA, CD3, and PD-L1 targeting trispecific antibody, in development for the treatment of multiple myeloma...Key findings: CDR101 demonstrated increased in vitro activity compared to clinical stage-like bispecific BCMA therapies. CDR101 induced superior T cell activation in bone marrow samples of MM patients and increased primary myeloma cell death by T cells. The concept of simultaneously blocking BCMA and PD-L1 has shown complete and more durable tumor eradication in a mouse xenograft model. The results clearly support the further development of CDR101. The company plans to initiate IND-enabling activities together with a partner."

Preclinical • Hematological Malignancies • Multiple Myeloma • Oncology

CDR-Life to Present at the American Society of Hematology’s 2021 Annual Meeting (GlobeNewswire) - "CDR-Life Inc...announced that preclinical data from the Company’s CDR101 candidate will be presented in a poster at the 63rd Annual American Society of Hematology (ASH) meeting being held in Atlanta, Georgia from December 11-14, 2021."

Preclinical • Oncology